Astra and Daiichi lay out their plan for a better Herceptin
The companies’ DS-8201 succeeds in breast cancer patients who had failed Kadcyla, and will go before the regulators later this year.
AAN 2019 – Viela Bio takes on Alexion in neuromyelitis optica
The Astrazeneca spinout is plugging data with its rare disease contender inebilizumab, but Alexion’s Soliris is one step ahead.
Astra shakes hands with Daiichi to take on Roche
UK group bets billions on an Her2 project slated for late-line patients and those with lower expression of the target protein.
Eisai and Biogen throw good money after bad
The companies’ decision to start a 1,500-patient Alzheimer’s disease study defies logic.
China’s blueprint for a checkpoint blocker price war
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
No, aducanumab is not an Alzheimer’s drug either
Failure at a futility analysis blows a big hole in Biogen's pipeline. Can the company buy in growth or will its valuation sink enough for it to become a target?
Bristol’s doomsday scenario: could Opdivo start shrinking next year?
Fears about flattening Opdivo sales were surely a major driver for Bristol's move for Celgene. To keep growing the checkpoint inhibitor needs some big clinical wins.
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
Duchenne muscular dystrophy attracts a new entrant in pamrevlumab, while Alnylam awaits more pivotal data with givosiran.
Asco-GU 2019 – checkpoint blockers might not be created equal after all
Until now all PD-(L)1 blockers were assumed to have broadly similar activity, with any differences being put down to trial design; the latest renal cancer data could…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.